Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth

NCT03292731 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

159

Enrollment

OTHER

Sponsor class

Stopped grant funding cycle ended

Conditions

Preterm Birth

Interventions

DRUG: 17-Hydroxyprogesterone caproate 250mg or 500 mg.
DRUG: Safety study of 500 mg dose.

Sponsor

Steve N. Caritis, MD

Collaborators

[object Object]